Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Amortization of Deferred Charges (2022 - 2023)

Adma Biologics (ADMA) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $877000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Amortization of Deferred Charges fell 9.97% year-over-year to $877000.0, compared with a TTM value of $877000.0 through Sep 2024, down 77.7%, and an annual FY2023 reading of $3.8 million, up 27.95% over the prior year.
  • Amortization of Deferred Charges was $877000.0 for Q4 2023 at Adma Biologics, down from $993000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $1.0 million in Q2 2022 and bottomed at $877000.0 in Q4 2023.